We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.40 | 0.20% | 1,708.60 | 1,708.60 | 1,708.80 | 1,713.00 | 1,699.40 | 1,701.60 | 11,522,668 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.27 | 70.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
13/3/2015 18:21 | Seems so TM :-) Good bounce today. | philanderer | |
13/3/2015 12:26 | All publicity is good publicity | tradermichael | |
13/3/2015 10:49 | Very touchy those American companies. | 2hoggy | |
12/3/2015 20:48 | more or less the same in the Telegraph... "n the FTSE 100, which enjoyed a second day of gains after adding 0.59pc to 6761.07, topping the leaderboard was drug group Astrazeneca. Hopes of positive news about its Brilinta heart drug when the results of clinical trials are posted at the weekend lifted the shares 4.1pc to £44.79. "Peers Shire and Glaxosmithkline were also big risers, putting on 2.7pc to £54.55 and 1.9pc to £15.48½ respectively. Glaxo was boosted by news it will sell half its stake in South Africa’s Aspen Pharmacare, which is expected to raise about $890m." | philanderer | |
12/3/2015 18:46 | Sorry...got that earlier post on potential value of Aspen share sale totally wrong..... T/O is a little under £1 billion for the South African entity. Good news on AZN and hope there is more to come with GSK..Sorry again. | cyberian | |
12/3/2015 18:13 | Might see a bid premium on GSK soon at this rate of future growth focus. | gwatson56 | |
12/3/2015 18:09 | "...Shares in Astrazeneca were lifted by comments from UBS which said that upcoming results from the Pegasus study of cardiovascular product Brilinta should drive "and thus should finally unlock Brilinta's multibillion-dollar potential". The bank said potential upside is "underappreciated" by the market. "Sector peer GlaxoSmithKline also rose on plans to sell half of its 12.4% stake in South Africa's largest drug company, Aspen Pharmacare" | philanderer | |
12/3/2015 18:04 | Deal? Or was it a Pharma correction as AZ also had a very good day? | jadeticl3 | |
12/3/2015 17:59 | Market liked that deal today :-) | philanderer | |
12/3/2015 13:41 | Yeah - just read in full and not quite as impressive protection by vaccine as suggested by the abstract of the article. About 80% of vaccinated animals survived a challenge infection with Staph. aureus. Paper is in Proceedings National Academy of Sciences but you won't be able to access yet as only available pre-publication to registered users. | tompion | |
12/3/2015 09:39 | Tompion do you have the article reference please? Not my field but sounds like an interesting read. Thanks! | yogaboy | |
12/3/2015 08:59 | Interesting paper published today in top scientific journal by Novartis showing they have a new vaccine that gives very impressive protection against S. aureus/MRSA infection in an animal model. Early days but looks very promising (this is my field). If I remember correctly the vaccine portfolio of Novartis goes to GSK. | tompion | |
12/3/2015 08:56 | 12th march Deutsche 'hold' reiterates | philanderer | |
12/3/2015 08:17 | By better understanding our bodies' electrical systems, GSK hopes to design technology small and smart enough to manipulate them and possibly conquer diseases from rheumatoid arthritis to asthma to diabetes. "If we look 10 years out, we should have a number of tiny devices—we call them bioelectronic medicines, because they are medicines—that will be treating conditions we use molecular medicines for today," Kris Famm, head of GSK's bioelectronics research and development unit, said in a telephone interview. "We are quite convinced this can be a class of new therapies." The technology GSK envisions, which is also known as electroceuticals, would involve implanting tiny devices on nerve bundles associated with specific organ functions. Its broadest applications are still years from the market, but Famm said he thinks the biology is becoming well-enough understood that the challenge becomes one of engineering: being able to miniaturize electronic devices enough to very specifically stimulate certain nerves, and do so in an autonomous way, detecting and reacting to problems in the body. The approach should be so specific it avoids the off-target side effects that can derail otherwise promising medicines, he said. | tradermichael | |
11/3/2015 07:54 | What would be the point of there being more than one broker if they said the same thing! | toffeeman | |
11/3/2015 07:33 | Both have time machines set in opposite directions | tradermichael | |
10/3/2015 16:50 | ....couple more from the clever people ;-) JP Morgan underweight tp 1250p Barclays overweight tp 1690p reiterations. | philanderer | |
10/3/2015 13:41 | GlaxoSmithKline: Jefferies lifts target to 1550p from 1420p and reiterates hold | philanderer | |
09/3/2015 10:07 | I stick to large cap shares in my approach. That means mostly FTSE100 and a very few from the FTSE250. | anhar | |
09/3/2015 08:18 | Some interesting posts on High Yield Portfolios, and GSK certainly has a good fit into that strategy. The best Boards I've seen for HYP shares is over on MotleyFool under "Investors Roundtable" and called " High Yield - HYP Practical" and "High Yield - Share Strategies" and | dragonsteeth |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions